

**AmeriHealth Insurance
Company of New Jersey
AmeriHealth HMO, Inc.**

8000 Midlantic Drive
Suite 333
Mt. Laurel, NJ 08054-1560

485 Route 1 South
Building C, 3rd Floor
Iselin, NJ 08830-3037



August 2001

Dear Broker:

The Food and Drug Administration has recently approved Gleevec[®] (imatinib mesylate), a chemotherapy drug used to treat Chronic Myelogenous Leukemia. Gleevec is being added to the list of drugs that require prior authorization by AmeriHealth and its affiliates. The intention of prior authorization is to ensure appropriate and cost-effective utilization. This addition to the prior authorization list is effective July 30, 2001. Any member who is currently using Gleevec[®] will be grandfathered and prior authorization will not be required for these individuals.

Also effective July 30, 2001, the drug Nexium[®] (esomeprazole) is being removed from the prior authorization list. Nexium is being added to the Select Drug Programsm formulary and will be covered at the formulary brand level.

As a result of the above changes, prescription drugs that require prior authorization are:

Aciphex[®] (rabeprazole)
Caverject[®] (alprostadil)
Celebrex[®] (celecoxib)
Edex[®] (alprostadil)
Enbrel[®] (etanercept)
Gleevec[®] (imatinib mesylate)
Mobic[®] (meloxicam)

MUSE[®] (alprostadil)
Prevacid[®] (lansoprazole)
Provigil[®] (modafenil)
Thalomid[®] (thalidomide)
Viagra[®] (sildenafil)
Vioxx[®] (rofecoxib)

Prescription drugs requiring prior authorization will not be covered by AmeriHealth if prior authorization is not obtained.

~~We are notifying affected groups of these changes. Please contact your Broker Representative if you have any questions.~~

Sincerely,

Linda M. Taylor

Linda M. Taylor
Vice President
Sales and Marketing
Southern New Jersey

A handwritten signature in black ink, appearing to read "J. Torella".

Joseph Torella
Vice President
Sales and Marketing
Northern New Jersey